News

In this interview, Madden shares how the company is evolving beyond COVID. He discusses the company’s preformed vesicle technology and its potential to make personalized genetic medicines shelf-ready, the clinical and infrastructure challenges facing n-of-1 therapies, and his view of where LNP technology is headed over the next five years.

Designing an in vivo cell therapy that appropriately balances efficacy and safety remains a significant challenge; however DARPin-conjugated LNP have shown promise on both counts in preclinical studies.

Combining pre-formed vesicles with nucleic acid cargo at the point of care can remove long-standing barriers to personalized nucleic acid therapeutics.

What differentiates us is our full “soup to nuts” capability—we support process development, scale-up, and provide clinical and regulatory expertise. This ability to de-risk partner programs is highly attractive.

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics.

Active targeting via site-specific ligand attachment, including DARPin conjugation, enables high-affinity cell recognition and has shown ~90% mRNA expression in human CD8⁺ T cells, supporting in-vivo CAR-T concepts.

Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines.

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics.